Stocky turns companies like CRISPR Therapeutics AG into a fun, safe way to learn investing — a virtual portfolio, live scores & charts, and real analyst data, with no real money.
Try Stocky free →Avoid. CRSP's 16/100 Value Compounder Score reflects stalled revenue growth and negative free cash flow, signaling the gene-editing hype cycle has deflated without commercialization breakthroughs. Leadership alignment at 60/100 offers modest governance discipline, but cannot offset the structural vulnerability: CRISPR therapy faces intense competition, lengthy FDA timelines, and unproven clinical economics—moats remain theoretical until clinical wins materialize.
Every stock is scored across six proprietary dimensions built for retail investors who want Buffett-quality analysis without a Bloomberg subscription. Here's the actual snapshot for CRISPR Therapeutics AG:
Quality + moat + leadership + valuation + sentiment fused into a single 0–100 number. When you see 22/100, you know instantly whether to dig deeper or skip.
Pricing power, switching costs, network effects, and 10-year ROIC data. Same framework Morningstar charges for — free inside Stocky.
Founder tenure, insider ownership, CEO pay reasonableness, long-term value creation. Six factors, one score — turns "trust the CEO" into evidence.
Customer concentration, supply chain, refinancing walls, regulatory exposure. Stocky maps knowable fragilities so you're never blindsided.
Every score backtested against real S&P 500 returns. See how "Elite" (90+ Verdict) picks have performed vs the index — no black boxes.
Analyst target shifts, insider buys, big moves — plus a monthly Portfolio Health Report telling you what's actually driving your returns.
Stocky rates CRISPR Therapeutics AG (CRSP) at 22/100 — an Avoid — fundamentals or risks are too weak. The score fuses business quality, moat width, leadership alignment, valuation and analyst signal into a single number. Avoid. CRSP's 16/100 Value Compounder Score reflects stalled revenue growth and negative free cash flow, signaling the gene-editing hype cycle has deflated without commercialization breakthroughs. Leadership alignment at 60/100 offers m
CRSP's current Stocky Verdict is 22/100, placing it in the "Avoid" band. This composite combines a 16/100 Compounder score, 60/100 Leadership, Moat rating, and analyst signal.
Stocky hasn't finalised a Moat Score for CRISPR Therapeutics AG yet — the analysis draws from ROIC trends, pricing power evidence, and competitive-position filings.
CRISPR Therapeutics AG scores 60/100 on Leadership Alignment. Higher = more founder involvement, higher insider ownership, sensible pay, and evidence of long-term capital allocation discipline.
CRISPR Therapeutics AG's Vulnerability Profile scores 0/100 (higher = more resilient). The profile flags customer concentration, supply chain, refinancing walls and regulatory risks specific to CRISPR Therapeutics AG.
Sign up free and unlock the full analysis on CRSP — the same tools professional analysts use, personalised to your portfolio:
Free forever tier includes 5 Verdict lookups a day. Plus €19/mo unlocks everything above. Cancel any time.
This page is just a preview. Open the live, interactive version for the full picture:
Or jump straight to the interactive dashboard for CRSP in the app.
